Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2MQ4JDl
via IFTTT